Company Overview and News

 
Pain Making It Rain In Midstream

2018-09-17 seekingalpha
Even with a full complement of tailwinds at play this week, midstream trading was choppy and the week ended with minimal gains. Those tailwinds include strong broad stock market (S&P 500 up for 5 straight days), oil price gains, spiking NGL prices, and wide location differentials for oil and NGLs. The big tailwind that's missing: investor enthusiasm, interest or even acknowledgement.
GBNXF GEI

16
No Encore, Deck Still Stacked For Midstream

2018-08-19 seekingalpha
The string of successive positive weeks for midstream ended this week. Midstream stocks were down roughly 1% across MLP and midstream indexes. Canadian Midstream stocks outperformed for the first time in a while. Utilities had a very strong week and the S&P was slightly positive. Oil prices continue to languish, now down 7 straight weeks, while natural gas prices continue to hold firm.
TGE CQP AMID PAGP ENB CEQP HCLP KMI HESM DKL TRP EBBNF OKE PAA ED KMR CVB NEE ENBBF TRP KEYUF LNG GLPRU ENLC ENB GBNXF ETP GLP SEMG TRGP KMRFZ

 
Gibson Energy, Inc. (GBNXF) CEO Steve Spaulding on Q2 2018 Results - Earnings Call Transcript

2018-08-13 seekingalpha
Good morning, ladies and gentlemen. Welcome to Gibson's 2018 Second Quarter Conference Call. Please be advised that this call is being recorded. I would now like to turn the meeting over to Mr. Mark Chyc-Cies, Vice President of Investor Relations. Mr. Chyc-Cies, please go ahead.
GBNXF GEI

6
Midstream Rally Secured

2018-08-12 seekingalpha
Midstream traded up for a 6th straight week, with MLPs again out front with a 2.2% total return. The MLP Index's YTD total return is now nearly 12% after being negative less than a month ago. The broad market struggled a bit, and midstream was a safe place to hide on Friday when the broad market sold off on Turkey's currency plunge.
KAAC APA KEYUF XOM SMLP IPL GBNXF EQT KMI EQGP PAA KMR PBA NFG IPPLF CVB KMRFZ FANG

11
Kinder Morgan Suddenly Has a Fat Bank Account to Go Shopping - Bloomberg

2018-05-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ENBBF TRP GEI KML ENB ENB GBNXF KMI EBBNF KMR CVB KMRFZ

50
CSX Recognizes 64 Customers with Chemical Safety Excellence Award

2018-05-29 globenewswire
JACKSONVILLE, Fla., May 29, 2018 (GLOBE NEWSWIRE) -- CSX Corporation (NASDAQ:CSX) recently recognized 64 customers for their commitment to the safe transportation of hazardous materials with CSX’s annual Chemical Safety Excellence Award.
INGR NGL MOS HES CVXTY ARKAF HUSKF MPC HSE AKE KMI CSX GFGY ARKAY KMR CVB GEI CVVTF GBNXF CVX CRDE ADM PBA KMRFZ

 
Gibson Energy's (GBNXF) CEO Steven Spaulding on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good morning, ladies and gentlemen, and welcome to Gibson's 2018 First Quarter Conference Call. Please be advised this call is being recorded.
GBNXF GEI

 
Gibson Energy Announces Voting Results for Election of Board of Directors

2018-05-09 globenewswire
CALGARY, Alberta, May 09, 2018 (GLOBE NEWSWIRE) -- Gibson Energy Inc. (“Gibson” or the “Company”), (TSX:GEI), announced today the voting results for the election of directors at the Company’s annual general meeting of shareholders that was held on May 9, 2018.
GBNXF GEI

 
Gibson Energy Announces 2018 First Quarter Results

2018-05-08 globenewswire
CALGARY, Alberta, May 08, 2018 (GLOBE NEWSWIRE) -- Gibson Energy Inc. (“Gibson” or the “Company”), (TSX:GEI), announced today its operating and financial results for the three months ended March 31, 2018.
GBNXF GEI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...